Laura Bukavina, MD
- Specialty: Urology-Urologic Oncology
-
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English, Ukrainian
Office Locations
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-5661
UH Parma Medical Arts Building 1 (11 mi.)
6681 Ridge Rd
Medical Arts Cntr 1 Ste 411
Parma, OH 44129
440-887-9139
Biography: Laura Bukavina, MD
Education
Fellowship | Urologic Oncology
Urologic Oncology - Fox Chase Cancer Center (2021 - 2023)
Residency | Urology
Urology - UH Cleveland Medical Center (2015 - 2021)
Research Fellowship
National Cancer Institute (NCI) (2014 - 2015)
Internship | Internal Medicine
Internal Medicine - Summa Health System (2013 - 2014)
Other Education
Johns Hopkins Bloomberg School Of Public Health (2017)
Medical Education
Northeast Ohio Medical University (NEOMED) (2013)
Undergraduate
Cleveland State University (2007)
About
Laura Bukavina, MD MPH MSc, is a urologic oncologist at University Hospitals Cleveland Medical Center, and an Assistant Professor of Urology at Case Western Reserve University School of medicine. Dr. Bukavina specializes in the care of patients with bladder, kidney, penile and prostate cancer.
Dr. Bukavina is a recipient of multiple grants and awards for her dedication to bladder and kidney cancer research, including the Robert Wood Johnson Foundation Health Data for Action, Bladder Cancer Advocacy Network Young Investigator, American Urologic Association (AUA) Research Scholar and Society of Women in Urology (SWIU) Elizabeth Pickett Award. She has been recognized for her research evaluating interplay between genetics, microbiome and tumor microenvironment. Further, her recognition by the American Association of Cancer Research (AACR) as one of the Top Women in Cancer Research underscores her standing as a pioneering figure among women cancer surgeon scientists.
Dr. Bukavina was born in Ukraine and raised in Cleveland. She earned her medical degree at Northeast Ohio Medical University, her Master of Epidemiology at Johns Hopkins and her Master of Immunology at Drexel University. She completed her urologic residency training at Case Western Reserve University and UH, followed by prestigious fellowship in urologic oncology at Fox Chase Cancer Center. Dr. Bukavina's research strikes a delicate balance between exploring the vast potential of the microbiome and revolutionizing bladder cancer treatment. In addition, she has received extensive training in complex kidney cancer care, serving as expert panelist on Society of Immunotherapy of Cancer (SITC) Guideline Committee for renal cell carcinoma.
Dr. Bukavina focuses on both open and minimally invasive surgical procedures in bladder, kidney, prostate and penile cancer, bringing to University Hospitals excellency in surgical expertise. She is well published in nerve preservation in bladder cancer, focusing on nerve and organ preservation in male and female cystectomies utilizing minimally invasive techniques.
In addition to surgeon scientist role, Dr. Bukavina is an associate editor for European Urology, most prestigious journal within urology, a Society of Urologic Oncology (YOU) board member, and a member of the Urology Times editorial board – all focused on advancing the surgical and scientific frontier of urologic oncology and clinical trial development.
On a more personal note, her ties to Ukraine have deeply influenced her philanthropic pursuits. She invests time and effort into various volunteer missions, with a primary aim of augmenting surgical skills and raising healthcare awareness in Ukraine.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Laura Bukavina did not disclose any Outside Relationships with Industry.